Also, in a combined analysis of the GeparQuattro [61] and GeparQuinto [106] trials, HER2-positive lymphocyte-predominant BC (LPBC) cases, with more than 50% TILs, had significantly higher pCR rates compared with non-LPBC types [107]. Here, ERBB2 is linked to breast cancer.